case_images: PMC6700860_01
case_images: Abdominal ultrasound (A) and computed tomography (B) at the onset of eosinophilic cholecystitis, demonstrating thickening of the gallbladder wall (white arrow) and cholecystolith (white arrowheads). Endoscopic findings of the left nasal cavity before (left panel) and 1 month after (right panel) cholecystectomy (C). Black arrowheads indicate nasal polyps in the superior meatus.
case_images: 10.1177_2152656719869607-fig1.jpg
case_images: PMC6700860_01_10.1177_2152656719869607-fig1.jpg
case_images: fig1-2152656719869607
case_images: After confirmation of the diagnosis with an abdominal ultrasound and a computed tomography scan (Figure 1(A) and (B)), a cholecystectomy was performed. We confirmed that nasal polyps were concomitantly reduced (from 6 to 4 in polyp score) with decreased blood eosinophils without any additional treatments 1 month after the cholecystectomy (Figure 1(C)) and were recurrence-free with no increase in blood eosinophils for at least 24 months (Figure 2).
case_images: Dynamics of eosinophil counts. Values indicate peripheral blood eosinophil counts at each point as follows; before second ESS; 1, 12, and 24 months after second ESS; onset of eosinophilic cholecystitis; and 1, 12, and 24 months after cholecystectomy. Values of inhaled corticosteroid indicate fluticasone propionate equivalent daily doses (microg). ESS, endoscopic sinus surgery; ICS, inhaled corticosteroid.
case_images: 10.1177_2152656719869607-fig2.jpg
case_images: PMC6700860_01_10.1177_2152656719869607-fig2.jpg
case_images: fig2-2152656719869607
case_images: We confirmed that nasal polyps were concomitantly reduced (from 6 to 4 in polyp score) with decreased blood eosinophils without any additional treatments 1 month after the cholecystectomy (Figure 1(C)) and were recurrence-free with no increase in blood eosinophils for at least 24 months (Figure 2).